Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 15:6:e39988.
doi: 10.2196/39988.

Refusal of Retreatment With Topical 5-Fluorouracil Among Patients With Actinic Keratosis: Qualitative Analysis

Affiliations

Refusal of Retreatment With Topical 5-Fluorouracil Among Patients With Actinic Keratosis: Qualitative Analysis

Rohan Singh et al. JMIR Dermatol. .

Abstract

Background: Actinic keratosis (AK) is a common premalignant skin lesion, and topical 5-fluorouracil (5-FU) is commonly used in field-directed therapy. However, 5-FU is associated with frequent local skin reactions.

Objective: This study aimed to qualitatively assess experiences among patients with AK who refuse retreatment with 5-FU.

Methods: Semistructured interviews were conducted with 10 adult participants who had received treatment with 5-FU for AK between January 1, 2017, and January 1, 2020, and refused future treatment with 5-FU. Results were analyzed using qualitative research methods.

Results: Although most participants had low concern upon having received a diagnosis of AK, most felt that treatment is very important. When initiating treatment with 5-FU, most cited recommendation by their health care professionals as the primary motivator and initially had low concern regarding treatment. The side effects associated with treatment were physically and psychosocially burdensome for most participants and led to temporary lifestyle adjustments. After treatment, most did not believe that their health care provider prepared them for treatment or were unsure. While half of the participants felt that 5-FU helped treat AKs, half were either unsure, due to premature discontinuation, or did not think that 5-FU treated their AKs.

Conclusions: 5-FU is one of the most commonly prescribed treatments for AKs, yet most patients experienced both a physical and psychosocial burden with the treatment. Inability to assess efficacy due to premature discontinuation secondary to 5-FU-related reactions is common, and shared decision-making, navigating treatment options, and taking into account patient preferences may be critical to help assure better adherence and outcomes. Although our study was limited by input from participants who refused future treatment with 5-FU, most stated that they would still continue to seek treatment for AKs in the future and would consider other topical treatments, especially if associated with a milder tolerability profile.

Keywords: actinic keratosis; adherence; attitude; attrition; cancer; carcinoma; dermatology; fluorouracil; lesion; malignancy; malignant; neoplasm; oncology; opinion; perception; pharmacological; pharmacotherapy; preference; qualitative; skin; solar keratosis; tolerability; topical 5-fluorouracil; topical treatment.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: SRF has received research and speaking or consulting support from a variety of companies including Galderma, GSK/Stiefel, Almirall, Leo Pharma, Baxter, Boeringer Ingelheim, Mylan, Celgene, Pfizer, Valeant, Taro, Abbvie, Cosmederm, Anacor, Astellas, Janssen, Lilly, Merck, Merz, Novartis, Regeneron, Sanofi, Novan, Parion, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate, and National Psoriasis Foundation. He is the founder and majority owner of www.DrScore.com and founder and part owner of Causa Research, a company dedicated to enhancing patients’ adherence to treatment.RS and SM have no conflicts to disclose.

Similar articles

Cited by

References

    1. Hashim PW, Chen T, Rigel D, Bhatia N, Kircik LH. Actinic keratosis: current therapies and insights into new treatments. J Drugs Dermatol. 2019 May 01;18(5):s161–166.S1545961619S0161X - PubMed
    1. Dianzani C, Conforti C, Giuffrida R, Corneli P, di Meo N, Farinazzo E, Moret A, Magaton Rizzi G, Zalaudek I. Current therapies for actinic keratosis. Int J Dermatol. 2020 Jun;59(6):677–684. doi: 10.1111/ijd.14767. - DOI - PubMed
    1. Maarouf M, Kromenacker BW, Brucks ES, Hendricks A, Shi VY. Reducing unpleasant side effects of topical 5-Fluorouracil treatment for actinic keratosis: a randomized controlled trial. J Dermatolog Treat. 2020 Mar;31(2):175–179. doi: 10.1080/09546634.2019.1589638. - DOI - PubMed
    1. Ezzedine K, Painchault C, Brignone M. Systematic literature review and network meta-analysis of the efficacy and acceptability of interventions in actinic keratoses. Acta Derm Venereol. 2021 Jan 04;101(1):adv00358. doi: 10.2340/00015555-3690. https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-3690 - DOI - DOI - PMC - PubMed
    1. Rosso JD, Armstrong AW, Berman B, Bhatia N, Cockerell C, Goldenberg G, Kirby J, Lebwohl M, Stein Gold L, Marson JW, Rigel DS. Advances and considerations in the management of actinic keratosis: an expert consensus panel report. J Drugs Dermatol. 2021 Aug 01;20(8):888–893. doi: 10.36849/JDD.6078.S1545961621P0888X - DOI - PubMed

LinkOut - more resources